44 results about "Musculoskeletal disorder" patented technology

A non-invasive device for assisting the treatment of any kind of musculoskeletal disorder, including but not exclusive of those of joint, limb, and spine disorders, includes a brace, sleeve, flexible pad, or any combination of the three, a plurality of electrodes disposed thereon, wherein the plurality of electrodes transmit at least three electrophysical modalities, and a stimulation control unit having interactive software to establish a controlled sequence of transmission of the at least three electrophysical modalities and communicating the controlled sequence to the electrodes. The at least three electrophysical modalities are chosen from a group consisting of neuromodulating functional electrical stimulation, transcutaneous electrical nerve stimulation, pulsed electromagnetic field stimulation, and heat therapy stimulation. The stimulation control unit also provides feedback data using the electrodes for monitoring and integration with the interactive software to analyze and assess biomechanical, neuromuscular, and neurological responses to the device.

Medical devices with novel spark gap electrode designs, able to control manually or automatically the electrodes gap are provided. These devices are used to generate a shock wave created by the rapid expansion and collapse of a plasma bubble that is formed between two spark gap electrodes placed in a special liquid medium, when a high differential voltage (kV) is applied to the electrodes. The resulting shock wave impacts a reflector to direct the energy into the body of an animal or a human toward the desired treatment location. This electro-hydraulic principle to create acoustic shock waves as a method of treatment is in use in the medical (lithotripsy, orthopedic use, wound treatment, burns, post-operative treatment, pain treatment, diagnosis, skin and organ transplantation supporting devices, arteriosclerosis treatment), cosmetic (treatment of scars and cellulite) and veterinary (treatment of musculoskeletal disorders) fields.

The present invention relates to the identification of two microRNAs, miR-499 and miR-208b, that repress fast skeletal muscle contractile protein genes. Expression of miR-499 and/or miR-208b can be used to repress fast fiber genes and activate slow fiber genes in the treatment of musculoskeletal disorders. Inhibition of miR-499 and/or miR-208b is proposed as a treatment for cardiac hypertrophy, myocardial infarction, and/or heart failure. Pharmaceutical compositions comprising antagonists and agonists of miR-499 and miR-208b function are also disclosed.

The present invention relates to methods, compositions, and kits for detecting and quantitating exosomes and exosomal biomarkers and the use of exosomes and exosomal biomarkers in diagnostic and prognostic methods for various diseases and disorders. Disease and disorders of the present invention include neurological disorders, immunological disorders, placental diseases, cancer, hematological disorders, kidney disease, gastrointestinal diseases, liver diseases, and musculoskeletal diseases

Disclosed are devices, systems and methods that utilize bioprinters to form scaffold structures in situ to facilitate treatment of the musculoskeletal or skin disorders in patients. A method for treating a musculoskeletal disorder of a patient includes positioning a bioprinter at a situs of the musculoskeletal disorder, or a situs of a skin injury, in the patient. The method includes extruding a hydrogel formulation from the bioprinter into the situs. The method includes curing the hydrogel formulation in the situs. The hydrogel formulation has a composition effective to generate, upon the curing, a scaffold structure in the situs to facilitate muscle hypertrophy, or skin wound healing, in the situs.

The present invention relates to gene therapy delivery and expression systems comprising at least one helper-dependent adenoviral vector containing a nucleic acid sequence encoding for proteoglycan 4 (PRG4) or a biologically active fragment thereof. The invention further relates to a pharmaceutical composition comprising a therapeutically effective amount of at least one helper-dependent adenoviral vector containing said nucleic acid sequence encoding for proteoglycan 4 (PRG4), or a homolog thereof from any other species, or a biologically active fragment thereof. The invention also relates to the use of the novel gene therapy delivery and expression system according to the invention for use in the prevention and/or treatment of camptodactyly-arthropathy-coxa vara-pericarditis (CACP), or a musculoskeletal disorder such as a joint disorder or joint disease.

A method for the treatment and prophylaxis of diseases or conditions associated with aging which includes oxidative stress and cancer. Such diseases or conditions are associated with a decrease or increase presence of one or a combination of one or more Carbonic Anhydrase isozymes I TO VII in the tissue of a subject. These diseases include but are not limited to chronic neurodegenerative diseases such as Alzheimer's disease, parkinson's disease, multiple sclerosis, autism, lou gehrig's disease, huntington's disease, immune disorders which includes systemic lupus erythematosus, diabetes mellitus; musculo-skeletal disorders which includes osteoporosis,arthritis, osteomalacia. Cancer which includes the breast, lung, colon, prostate gland, ovary, esophagus, liver, rectum. The method comprises administering to the patient a pharmaceutically effective non toxic amount of one or a combination of one or more compounds that increases or decreases the level of one or more Cell Specific Carbonic Anhydrase Enzymes whose levels have been increased or decreased in the tissue of the subject. Such compound maybe the Cell Specific Carbonic Anhydrase Enzymes I to VII. A compound that when absorbed reacts or dissociates to form cell specific carbonic enzymes or one or more compounds that when administered promotes the increase or decrease level of one or more cell specific Carbonic anhydrase I,II,III,IV,V,VI,VII. As growth factors of stem cells as an alternative to stem cell therapy. These methods includes the administering of one or a combination of one or more of these compounds over an extended period of time ranging from 6 months until the patient dies.

The disclosure is directed to a system and methods for dynamic diagnosis of musculoskeletal conditions. The methods include monitoring at least one body part of a subject with at least one sensor, the at least one sensor configured to detect motions of the at least one body part of the subject, the at least one sensor comprising a Micro Electro Mechanical System (MEMS) sensor. The at least one sensor transmits kinematic data to a signature-comparing device. The methods include obtaining composite signatures of the subject based on the kinematic data, the composite signatures comprising at least one motion signature. The methods also include comparing the composite signatures of the subject to a normal composite signature to determine whether a difference between the composite signatures of the subject and the normal composite signatures is larger than a pre-determined threshold.

The present invention relates to a composition comprising an oligomeric compound comprising one or more tricyclo-deoxyribonucleic acid (tc-DNA) nucleosides and one or more lipid moiety, wherein said one or more lipid moiety is covalently linked to said oligomeric compound either directly or via a spacer, and wherein preferably said oligomeric compound comprises from 5 to 40 monomer subunits, as well as pharmaceutical compositions thereof and their uses in the prevention or treatment of neuromuscular or musculoskeletal diseases such as Duchenne muscular dystrophy or Steinert disease.

An apparatus for determining a musculoskeletal disease may be disclosed. The apparatus may include a motion protocol learning unit configured to generate a first motion protocol used to determine a musculoskeletal disease in advance through learning, a motion protocol recognition model unit configured to generate a motion protocol recognition model for determining a musculoskeletal disease by using information of the first motion protocol, a body pose estimator configured to receive a user image to be recognized and estimate a body pose from the user image, and a disease classification and prediction unit configured to determine a musculoskeletal disease by matching the body pose and the motion protocol recognition model.

The invention discloses an external traditional Chinese medicine composition for treating various muscle and bone diseases and a preparation device thereof. The traditional Chinese medicine composition provided by the invention is divided into a formula I and a formula II. The formula 1 is used for stopping bleeding, stopping pain, and relieving swelling, and can be used for treating early traumatic injury; and the formula 2 is used for dispelling pathogenic wind and cold, removing dampness, promoting blood circulation, removing blood stasis, dredging collaterals, and promoting bone regeneration. The formula I and the formula II are matched for use, and have good effects. Meanwhile, all the raw materials of the invention are reasonably matched and have synergistic effect, and the formulasare combined and matched, so that the composition has the effects of dispelling pathogenic wind and cold, removing dampness, stopping bleeding, stopping pain, promoting blood circulation, dispelling blood stasis, and dredging channels and collaterals, and is widely applicable to myofascitis, lumbar muscle strain, cervical and lumbar disc herniation and senile osteoporosis accompanied with compression fracture caused by traumatic injury, sprain and exogenous evil, blue soft tissues and blood stasis caused by fracture caused by trauma, and pain, swelling, and limb function limitation caused by bone injury.

The present disclosure relates to a novel musculoskeletal stem cell (MSSC) differentiated from an ESC (embryonic stem cell) or an iPSC (induced pluripotent stem cell). The musculoskeletal stem cell of the present disclosure can be easily induced from a human embryonic stem cell or a human-derived pluripotent stem cell and can be effectively differentiated not only into bone but also into cartilage, tendon and muscle. Accordingly, it can be usefully used for prevention or treatment of various musculoskeletal diseases.

Provided herein are compositions containing dehydrated placental tissue particulates, methods of making the compositions and methods for treating various musculoskeletal disorders and other conditions using such compositions, including osteoarthritis (OA), degenerative disc disease, tendonitis, plantar fasciitis, and pain associated therewith.